Acro Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-0.1	-0.04	-8.81	-15.87	-7.7	Upgrade
Asset Writedown & Restructuring Costs	-	-	0.01	-	-	Upgrade
Stock-Based Compensation	-	-	8.06	15.71	7.65	Upgrade
Provision & Write-off of Bad Debts	-	-	0.48	-	-	Upgrade
Other Operating Activities	-0.05	0	0	0	0	Upgrade
Change in Accounts Receivable	-	-	0.16	-0.04	-0.6	Upgrade
Change in Inventory	-	-	-	-	0.94	Upgrade
Change in Accounts Payable	-0.04	0	0.08	0.05	0	Upgrade
Change in Other Net Operating Assets	-0.01	0	-0	-0	-0	Upgrade
Operating Cash Flow	-0.2	-0.04	-0.02	-0.15	0.3	Upgrade
Short-Term Debt Issued	0.2	0.04	0.01	0.06	0.02	Upgrade
Total Debt Issued	0.2	0.04	0.01	0.06	0.02	Upgrade
Short-Term Debt Repaid	-	-	-	-	-0.24	Upgrade
Total Debt Repaid	-	-	-	-	-0.24	Upgrade
Net Debt Issued (Repaid)	0.2	0.04	0.01	0.06	-0.22	Upgrade
Financing Cash Flow	0.2	0.04	0.01	0.06	-0.22	Upgrade
Net Cash Flow	0	0	-0.01	-0.09	0.08	Upgrade
Levered Free Cash Flow	-0.21	-0.03	3.29	5.8	3.19	Upgrade
Unlevered Free Cash Flow	-0.2	-0.03	3.29	5.8	3.19	Upgrade
Change in Working Capital	-0.04	0	0.24	0.01	0.34	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.